Table 1.
Baseline characteristics of patients
| ABC/3TC/RPV (n = 66) (%) | ABC/3TC/EFV or boosted PIs (n = 104) (%) | p-value | |
|---|---|---|---|
| Age, years, median (IQR) | 35 (28–46) | 30 (30–49) | 0.04 |
| Male | 63 (95.4) | 95 (91.3) | 0.37 |
| Race | 0.40 | ||
| Chinese | 45 (68.2) | 73 (70.2) | |
| Malay | 16 (24.2) | 21 (20.2) | |
| Indian | 5 (7.5) | 5 (4.8) | |
| Others | 0 (0) | 5 (4.8) | |
| HIV transmission route | 0.20 | ||
| Homosexual | 42 (63.6) | 54 (52) | |
| Heterosexual | 12 (18.2) | 30 (28.9) | |
| Bisexual | 8 (12.1) | 18 (17.3) | |
| IVDU + sexual contact | 2 (3.0) | 1 (1.1) | |
| Others | 2 (3.0) | 1 (1) | |
| Baseline viral load (copies/ml) | 0.42 | ||
| < 10,000 | 21 (31.8) | 24 (23.1) | |
| 10,000–50,000 | 34 (51.5) | 58 (55.8) | |
| > 50,000 | 11 (16.7) | 22 (21.2) | |
| Baseline CD4 count | 0.37 | ||
| 200–350 | 21 (31.8) | 44 (42.3) | |
| > 350–500 | 21 (31.8) | 30 (28.8) | |
| > 500 | 24 (36.4) | 30 (28.8) | |
| AIDS defining illness | 0 (0) | 0 (0) | NA |
| HCV co-infection | 2 (3.0) | 3 (2.9) | 0.95 |
| Genotype test at diagnosis | 29 (44.0) | 55 (52.9) | 0.26 |
| Time from diagnosis to treatment, days, median (IQR) | 67 (45–215) | 84 (48–351) | 0.27 |
| HLA B*5701 | <0.01 | ||
| Positive | 0 (0) | 1 (1.0) | |
| Negative | 61 (92.4) | 65 (62.5) | |
| Not done | 5 (7.6) | 38 (36.5) | |
| Comorbidities | |||
| Diabetes mellitus | 5 (7.5) | 6 (5.8) | 0.64 |
| Hypertension | 7 (10.6) | 9 (8.6) | 0.67 |
| Hyperlipidemia | 5 (7.6) | 9 (8.7) | 0.80 |
| IHD/CAD | 1 (1.5) | 2 (1.9) | 0.84 |
| Congestive cardiac failure | 0 (0) | 0 (0) | NA |
| Chronic liver disease | 0 (0) | 0 (0) | NA |
| Chronic kidney disease | 0 (0) | 3 (2.9) | 0.16 |
| Cancer | 0 (0) | 1 (1) | 0.42 |
| CVA | 0 (0) | 0 (0) | NA |
| Osteoporosis | 0 (0) | 0 (0) | NA |
ABC abacavir, 3TC lamivudine, RPV rilpivirine, IQR interquartile range, IVDU intravenous drug use, AIDS acquired immunodeficiency syndrome, HCV hepatitis C Virus, IHD ischaemic heart disease, CAD coronary artery disease, CVA cerebrovascular accident